Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Indian equity markets march ahead
Fri, 14 Sep 11:30 am

Indian equity markets continued to trade in the green during the last two hours of trade on back of buying across index heavyweights. Led by realty and banking stocks, all sectoral indices traded positively.

The BSE-Sensex is trading higher by 387 points and NSE-Nifty is trading up by 119 points. BSE Mid Cap and BSE Small Cap indices are currently up by 1.1% each. The rupee is trading at 54.75 to the US dollar.

Auto stocks are trading strong led by Tata Motors and TVS Motors. According to a leading financial daily, Hero Motocorp has decided to partner with Italian two-wheeler design firm Engines Engineering to bring in next-generation products. Under the partnership, Engines Engineering will impart technological know-how in terms of designing for future products to be launched by Hero. The Indian two-wheeler company is looking at offering cutting-edge technology and visionary styling in all their future products. After its break up with Honda, Hero has gotten into three partnerships including this latest one. Earlier, it tied up with US-based Erik Buell Racing and Austrian engine developer AVL.

Pharma stocks are trading strong led by Piramal Healthcare and Strides Arcolab. According to a leading financial daily, Glenmark Pharma has entered the phase II in clinical trials for its new drug molecule aimed at treating ulcerative colitis (UC). The company's subsidiary Glenmark Pharmaceuticals SA will conduct trials at multiple clinical sites in North America and Europe to investigate the efficacy and safety of the new molecule GBR 500. It is expected that the trial will include nearly eighty four patients with moderate to severe ulcerative colitis. This Phase II clinical trial is part of a strategic global collaboration between Glenmark and Sanofi to investigate GBR 500 for the treatment of chronic inflammatory disorders. Sanofi has been licensed the rights to all therapeutic indications and is conducting the clinical development program, including this trial.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Indian equity markets march ahead". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Feb 20, 2018 (Close)